161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Material disclosure
U.S. FDA Approval of AVLAYAH⢠(tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Investor Presentation
Announce $275 Million Royalty Funding Agreement
FY 2024
Q3
Q2
Q1
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence